Vaxxinity to Present at Upcoming Investor Conferences in September
September 01 2022 - 8:00AM
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the
development of a new class of immunotherapeutic vaccines, today
announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity,
will present at the following investor conferences in September:
H.C. Wainwright 24th Annual Global Investment
ConferenceDate: Monday, September 12, 2022Time: 10:00 a.m.
– 10:30 a.m. (ET)Presentation Format: Corporate Presentation
Baird Global Healthcare Conference Date:
Tuesday, September 13, 2022Time: 3:10 p.m. – 3:40 p.m.
(ET)Presentation Format: Fireside Chat
A live webcast of the presentation and fireside chat can be
accessed under “Events & Presentations” in the Investor section
of the Company’s website, and will be available for replay for 90
days following each event. All presentation times are subject to
change.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company
committed to democratizing healthcare across the globe. The company
is pioneering a new class of synthetic, peptide-based
immunotherapeutic vaccines aimed at disrupting the existing
treatment paradigm for chronic disease, increasingly dominated by
monoclonal antibodies, which suffer from prohibitive costs and
cumbersome administration. The company’s proprietary technology
platform has enabled the innovation of novel pipeline candidates
designed to bring the efficiency of vaccines to the treatment of
chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and
hypercholesterolemia. The technology is also implemented as part of
a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to
achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc., visit
http://www.vaxxinity.com and follow us on social media
@vaxxinity.
Forward-looking Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. The use of certain words, including "potentially," and "will"
and similar expressions, are intended to identify forward-looking
statements. These forward-looking statements involve substantial
risks and uncertainties, and are based on the current expectations
and assumptions of Vaxxinity’s management. Forward-looking
statements include statements about the development of a new class
of immunotherapeutic vaccines and the innovation and efficacy of
Vaxxinity’s product candidates. Various important factors could
cause actual results or events to differ materially from those that
may be expressed or implied by our forward-looking statements.
Additional important factors to be considered in connection with
forward-looking statements are described in the "Risk Factors"
section of the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 24, 2022 and other
reports we file with the Securities and Exchange Commission. The
forward-looking statements are made as of this date and Vaxxinity
does not undertake any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor ContactBenjamin
Matonebenm@vaxxinity.com
Press ContactKaren Chasemedia@vaxxinity.com
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Sep 2023 to Sep 2024